News Related to FGFR Inhibitor

Related coverage linked through entity extraction aliases.

International Workshops Prioritize Drug Targets for Childhood Medulloblastoma and Rhabdoid Tumours

Jul 13, 2026

International expert workshops have identified priority therapeutic targets for medulloblastoma and rhabdoid tumours, two rare childhood cancers. For medulloblastoma, key priorities include SRC degradation, c-MYC/MYCN inhibition, and B7-H3 targeted approaches. For rhabdoid tumours, DCAF5 and MDM2 were highlighted, with EZH2 degraders showing potential.

FDA Clears Abbisko's FGFR Inhibitor for Achondroplasia as BridgeBio Reports Phase 3 Success

Apr 01, 2026

The FDA has cleared Abbisko Therapeutics' IND application for ABSK061, an oral FGFR2/3 inhibitor for achondroplasia, while BridgeBio reports positive Phase 3 results for its oral infigratinib in the same condition. Both companies are advancing oral therapies targeting FGFR3 overactivity in this genetic growth disorder.